Thalassemia and Hemoglobinopathy Evaluation
Hemoglobinopathies are the group of inherited disorders caused by the production of structurally abnormal hemoglobin molecules. Approximately 7% of the world’s population carries a mutation for at least one type of hemoglobinopathy. Sickle cell anemia, thalassemia, hemoglobin C disease, hemoglobin SC disease, hemoglobin E disease, and methemoglobinemia are some commonly encountered hemoglobinopathies.
Major adult hemoglobin (HbA) is composed of two α-chains and two β-chains encoded by four α-globin genes on chromosome 16 and two β-globin gene family on chromosome 11. Unbalanced synthesis of either α- or β-globin chains results in thalassemia, one of the commonest autosomal recessive disorders annually affecting over 120,000 births worldwide. Decreased or absent synthesis of β-globin is known as β-thalassemia and commonly found in persons of North African, the Mediterranean, Middle Eastern and South-East Asian descent. More than 300 different mutations of the β-globin gene or its promoter have been identified, of which point mutations are most common. In the β-thalassemia minor, only one gene is affected resulting in decreased synthesis of β-globin. Affected individuals are asymptomatic and usually do not require specific treatment. On hemoglobin electrophoresis the percentage of HbA2 and HbF fractions may slightly elevated due to compensatory increases in the production of gamma chains (HbF) and delta chains (HbA2). β-thalassemia major is the severe form, which is characterized by severe impairment or absence of β-chain production. As a result, excess α-chains precipitate in the cell and cause red cell destruction and ineffective erythropoiesis. It is characterized by increase fraction of HbA2, HbF in blood.
Decrease synthesis or absence of α-chains is known as α-thalassemia, which is generally associated with deletional mutations in one or more of the four α-globin genes. Alpha-thalassemia is prevalent in South-East Asian populations with carrier rates up to 50%. Clinically, the severity of alpha-thalassemia is proportional to the number of mutated α-globin genes. Individuals with a mutation in only one gene (-α/αα) are termed ‘silent carriers’ and have no clinical manifestations. When two α-globin genes are mutated (–/αα or (-α/-α), it causes α-thalassemia trait, with generally mild symptoms. When 3 α-globin genes are dysfunctional (–/-α), it causes Hemoglobin H disease. Such individuals have moderate to severe hemolytic anemia and are characterized by increase fraction of HbH (β-chain tetramers) and Hb Bart’s (γ-chain tetramers). Hydrops fetalis results when all four alpha chain genes are deleted (–/–) the most severe form of α-thalassemia. In addition to not being able to produce adult HbA the fetus cannot make HbF (α2γ2) therefore fetus becomes severely anemic which ultimately leads to fetal hydrops and death in utero. It is important to note that the deletion of two alpha genes on one chromosome 16 (cis) is much more common in individuals on South East Asian decent than in those of African descent. Therefore, both HbH disease and Hydrops fetalis are typically only seen in individuals of South East Asian descent.
Routine laboratory picture of clinically significant thalassemia and other variants includes decreased hemoglobin A with microcytic red cells and increased reticulocytes counts. Patients with suspected hemoglobinopathy should be evaluated with hemoglobin electrophoresis to identify the major hemoglobin types present. Typically, this is followed with molecular analysis that includes α-globin gene analysis, α-globin gene sequencing, β-globin gene sequencing, β-globin cluster locus deletion/duplication and γ-globin gene sequencing.
- Diagnosis of thalassemia and its classification
- Differential diagnosis of hemoglobinopathies
- Diagnosis of hereditary persistence of hemoglobin (HPFH)
| Hemoglobinopathy | HbA | HbA₂ | HbF | HbS | HbC |
|---|---|---|---|---|---|
| β-Thalassemia minor | >80% | 3.5–8% | 2–5% | – | – |
| β-Thalassemia intermedia | 25–60% | 5–10% | 30–70% | – | – |
| β-Thalassemia major | 15–30% | Trace | 70–90% | – | – |
| Sickle cell trait | 55–68% | – | 1–40% | 33–45% | – |
| Sickle cell anemia | – | – | 1–40% | 65–99% | – |
| Hemoglobin C trait | 70% | – | – | – | 30% |
| Hemoglobin C disease | – | 5% | – | – | 95% |
| Sickle C disease | – | – | – | 45–55% | 45–55% |
| Hb Fraction | Chain Composition | % Fraction of Total Hemoglobin |
| HbA | α2β2 | >95% |
| HbF | α2γ2 | <2% |
| HbA2 | α2𝛿2 | 1.5 – 3.7% |
Whole Blood (EDTA).
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
3-7 days.
- Lancet 2018;391:155-167. [PMID: 2877442]
- Talanta 2018;183:216-222. [PMID: 29567167]
- Clin Chem 2000;46:1284-90. [PMID: 10926923]
- Clin Biochem 1991;24:363-74. [PMID: 1959228]
- Rees DC, Arya R, The haemoglobinopathies. Ed Marshall WJ et al, In Clinical Biochemistry Metabolic and clinical aspects, 3rd edition, Chruchill Livingstone 2014, page 550-559